Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Sales: 2010-2025

Historic Return on Sales for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to -0.79%.

  • China Pharma Holdings' Return on Sales rose 7.00% to -0.79% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.79%, marking a year-over-year increase of 7.00%. This contributed to the annual value of -1.05% for FY2024, which is 61.00% down from last year.
  • Latest data reveals that China Pharma Holdings reported Return on Sales of -0.79% as of Q3 2025, which was up 5.35% from -0.83% recorded in Q2 2025.
  • China Pharma Holdings' Return on Sales' 5-year high stood at -0.26% during Q1 2021, with a 5-year trough of -1.06% in Q1 2025.
  • Moreover, its 3-year median value for Return on Sales was -0.70% (2024), whereas its average is -0.68%.
  • Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 189bps in 2021, then plummeted by 61bps in 2024.
  • Over the past 5 years, China Pharma Holdings' Return on Sales (Quarterly) stood at -0.35% in 2021, then declined by 14bps to -0.49% in 2022, then climbed by 5bps to -0.44% in 2023, then plummeted by 61bps to -1.05% in 2024, then climbed by 7bps to -0.79% in 2025.
  • Its last three reported values are -0.79% in Q3 2025, -0.83% for Q2 2025, and -1.06% during Q1 2025.